Background
It is unclear whether HIV infection affects the long‐term prognosis after an acute coronary syndrome (ACS). The objective of the current study was to compare rates of major adverse cardiac and cerebrovascular events after a first ACS between people living with HIV (PLHIV) and HIV‐uninfected (HIV−) patients, and to identify determinants of cardiovascular prognosis.
Methods and Results
Consecutive PLHIV and matched HIV− patients with a first episode of ACS were enrolled in 23 coronary intensive care units in France. Patients were matched for age, sex, and ACS type. The primary end point was major adverse cardiac and cerebrovascular events (cardiac death, recurrent ACS, recurrent coronary revascularization, and stroke) at 36‐month follow‐up. A total of 103 PLHIV and 195 HIV− patients (mean age, 49 years [SD, 9 years]; 94.0% men) were included. After a mean of 36.6 months (SD, 6.1 months) of follow‐up, the risk of major adverse cardiac and cerebrovascular events was not statistically significant between PLHIV and HIV− patients (17.8% and 15.1%,
P
=0.22; multivariable hazard ratio [HR], 1.60; 95% CI, 0.67–3.82 [
P
=0.29]). Recurrence of ACS was more frequent among PLHIV (multivariable HR, 6.31; 95% CI, 1.32–30.21 [
P
=0.02]). Stratified multivariable Cox models showed that HIV infection was the only independent predictor for ACS recurrence. PLHIV were less likely to stop smoking (47% versus 75%;
P
=0.01) and had smaller total cholesterol decreases (–22.3 versus –35.0 mg/dL;
P
=0.04).
Conclusions
Although the overall risk of major adverse cardiac and cerebrovascular events was not statistically significant between PLHIV and HIV− individuals, PLHIV had a higher rate of recurrent ACS.
Registration
URL:
https://www.clinicaltrials.gov
; Unique identifier: NCT00139958.
The purpose of this study was to evaluate the success rate of the SERF EVL evolution implants (Décines, France) through a 5-year longitudinal multicentric study. Patients from 3 clinicians working in 3 different private practices (Grenoble, Nice, and Paris) and familiar with this implant system were included in this study; 413 patients and 1198 implants were followed over 5 years. The implant sites and implant types were recorded at the time of placement. The patients were followed yearly and controlled at the end of the study. The criterion for treatment evaluation or success was a qualitative variable related to 4 possible treatment outcomes: success, failure, ailing, and lost (dropout patients). Different variables (sex, bone quantity and quality at the implant site, location) were submitted to the chi-square test. A survival curve was established over 5 years according to the Kaplan Meyer method. The clinical follow-up was 3.1 +/- 1.2 years (ie, 1 to 6 years). At the end of this follow-up period, 1163 implants were classified as successful, 19 as failures, 12 as ailing, and 4 as lost (dropout). This implant system thus presented an overall success rate of 97.08%, over 5 years, independent of implant location, and for patient indications commonly encountered in private practice.
The major objective of the Trimetazidine European Multicenter Study (TEMS) was to compare in a double-blind trial the anti-ischemic effects of trimetazidine (20 mg 3 times daily) with those of propranolol (40 mg 3 times daily). The inclusion criteria were based on an abnormal response to a multistage exercise test. After 3 months of treatment the improvements noted in all exercise testing data were similar in the trimetazidine and propranolol groups; similar data were obtained for the grades and severity of anginal attacks during daily life (from patient diaries). A 24-hour Holter monitoring was performed at entry and at the end of the study, but an abnormal Holter monitoring (1-mm ST-segment depression during at least 1 minute) was not an inclusion criterion. This explains why at entry only 50% of the patients in both groups had an abnormal Holter recording. After 3 months of treatment, there were no significant differences between the 2 groups, but we observed a trend toward a decrease in ambulatory ischemia in the trimetazidine group and a trend toward an increase in ambulatory ischemia in the propranolol group. These data in the propranolol group are in total disagreement with the available literature on beta blockers, which was due to a totally erratic behavior pattern in 2 patients in the propranolol group. When we excluded these 2 erratic cases from the propranolol group and extended our analysis to all available paired comparisons (day -14 to day 30 and day 0 to day 90), we were able to compare 44 and 60 observations, both off therapy and on either propranolol or trimetazidine, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.